Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
18.7M
-
Shares change
-
+6.21M
-
Total reported value, excl. options
-
$855M
-
Value change
-
+$304M
-
Put/Call ratio
-
3.62
-
Number of buys
-
96
-
Number of sells
-
-37
-
Price
-
$45.71
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2018
152 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2018.
CRISPR Therapeutics AG - Common Stock (CRSP) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.7M shares
of 86M outstanding shares and own 21.77% of the company stock.
Largest 10 shareholders include Versant Venture Management, LLC (4.61M shares), NEA Management Company, LLC (3.48M shares), Abingworth LLP (1.89M shares), WELLINGTON MANAGEMENT GROUP LLP (920K shares), FRANKLIN RESOURCES INC (712K shares), FARALLON CAPITAL MANAGEMENT LLC (645K shares), New Leaf Venture Partners, L.L.C. (596K shares), BlackRock Inc. (572K shares), Clough Capital Partners L P (560K shares), and Marshall Wace North America L.P. (477K shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.